Company news
Sera Prognostics, Inc. (NASDAQ:SERA) news
Sera Prognostics, Inc. news releases on 6ix. Latest, Aug 19, 2026: SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
Press releases & updates
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
August 19, 2026
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
August 12, 2026
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
July 29, 2026
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
July 9, 2026
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
June 30, 2026
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
June 23, 2026
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
June 23, 2026
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
June 1, 2026
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
May 6, 2026
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
April 22, 2026
SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
March 17, 2026
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026
March 4, 2026
SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE
February 17, 2026
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
January 7, 2026
Sera Announces Publication Acceptance for PRIME Study
November 24, 2025
SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
November 13, 2025
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025
October 30, 2025
Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer
October 1, 2025
SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE
August 28, 2025
SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
August 6, 2025
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025
July 29, 2025
SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
May 29, 2025
SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE
May 14, 2025
SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER
May 8, 2025
SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
May 7, 2025
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025
April 24, 2025
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
March 19, 2025
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
March 19, 2025
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
March 11, 2025
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
February 21, 2025
Sera Prognostics Announces Proposed Public Offering
February 9, 2025
Sera Prognostics Announces Pricing of $50 Million Public Offering
February 9, 2025
Sera Prognostics to Host Virtual R&D Day on January 31
January 26, 2025
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
December 3, 2024
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
November 5, 2024
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
October 27, 2024
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
August 6, 2024
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
July 24, 2024
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
July 8, 2024
SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION
June 30, 2024
SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
May 27, 2024
SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
May 7, 2024
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024
April 28, 2024
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS
March 19, 2024
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024
March 3, 2024
SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS
December 5, 2023
SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
November 7, 2023
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023
October 24, 2023
SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
August 8, 2023
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023
July 30, 2023